SG11201803581VA - Chimeric RSV, Immunogenic Compositions, and Methods of Use - Google Patents
Chimeric RSV, Immunogenic Compositions, and Methods of UseInfo
- Publication number
- SG11201803581VA SG11201803581VA SG11201803581VA SG11201803581VA SG11201803581VA SG 11201803581V A SG11201803581V A SG 11201803581VA SG 11201803581V A SG11201803581V A SG 11201803581VA SG 11201803581V A SG11201803581V A SG 11201803581VA SG 11201803581V A SG11201803581V A SG 11201803581VA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- immunogenic compositions
- chimeric rsv
- rsv
- chimeric
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562247962P | 2015-10-29 | 2015-10-29 | |
| US201662334547P | 2016-05-11 | 2016-05-11 | |
| PCT/US2016/058976 WO2017075125A1 (en) | 2015-10-29 | 2016-10-27 | Chimeric RSV, Immunogenic Compositions, and Methods of Use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803581VA true SG11201803581VA (en) | 2018-05-30 |
Family
ID=58630734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803581VA SG11201803581VA (en) | 2015-10-29 | 2016-10-27 | Chimeric RSV, Immunogenic Compositions, and Methods of Use |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11235050B2 (https=) |
| EP (1) | EP3368547A4 (https=) |
| JP (2) | JP7311872B2 (https=) |
| KR (1) | KR20180085730A (https=) |
| CN (1) | CN108602858A (https=) |
| BR (1) | BR112018008708A2 (https=) |
| CA (1) | CA3003726A1 (https=) |
| MX (1) | MX2018005462A (https=) |
| SG (1) | SG11201803581VA (https=) |
| WO (1) | WO2017075125A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3798310A1 (en) | 2013-03-14 | 2021-03-31 | Emory University | Recombinant rsv with silent mutations, vaccines, and methods related thereto |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| IL262108B2 (en) | 2016-04-05 | 2023-04-01 | Janssen Vaccines Prevention B V | Soluble pre-fusion rsv f proteins are stabilized |
| HUE073526T2 (hu) | 2017-04-04 | 2026-01-28 | Univ Washington | Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata |
| WO2019169120A1 (en) | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
| MX2021005607A (es) * | 2018-11-13 | 2021-06-30 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del vrs estabilizadas. |
| EP3923983A4 (en) | 2019-02-11 | 2023-02-22 | Emory University | CHIMERIC RSV AND HMPV F PROTEINS, IMMUNOGENIC COMPOSITIONS AND METHODS OF USE |
| EP4319880A4 (en) * | 2021-04-08 | 2025-03-19 | Codagenix Inc. | Method of eliciting an immune response against respiratory syncytial virus |
| US12304929B2 (en) * | 2021-04-12 | 2025-05-20 | Sk Bioscience Co., Ltd. | Recombinant RSV live vaccine strain and the preparing method thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| IL105456A (en) | 1992-04-21 | 1996-12-05 | American Home Prod | Vaccines of attenuated respiratory syncytial virus |
| AT401526B (de) | 1993-02-10 | 1996-09-25 | Scheirer Winfried | Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung |
| ATE257175T1 (de) | 1994-07-18 | 2004-01-15 | Conzelmann Karl Klaus Prof Dr | Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus |
| US7465574B2 (en) | 1994-09-30 | 2008-12-16 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
| US6264957B1 (en) | 1995-09-27 | 2001-07-24 | The United States Of America As Represented By The Department Of Health And Human Services | Product of infectious respiratory syncytial virus from cloned nucleotide sequences |
| US7485440B2 (en) | 1995-09-27 | 2009-02-03 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
| US6689367B1 (en) | 1995-09-27 | 2004-02-10 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
| US6923971B2 (en) | 1995-09-27 | 2005-08-02 | The United States Of America As Represented By The Department Of Health & Human Services | Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes |
| US7846455B2 (en) | 1996-07-15 | 2010-12-07 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated chimeric respiratory syncytial virus |
| US6713066B1 (en) | 1996-07-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
| US6214805B1 (en) | 1996-02-15 | 2001-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
| US6699476B1 (en) | 1996-07-15 | 2004-03-02 | Peter L. Collins | Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules |
| WO1998002530A1 (en) | 1996-07-15 | 1998-01-22 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| US6074859A (en) | 1997-07-08 | 2000-06-13 | Kikkoman Corporation | Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein |
| US20040005542A1 (en) | 2001-06-22 | 2004-01-08 | Krempl Christine D | Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes |
| US20020018780A1 (en) * | 2000-05-25 | 2002-02-14 | Scott Koenig | Epitope-based vaccine for respiratory syncytial virus F-protein |
| EP1613345B1 (en) | 2003-03-28 | 2010-05-26 | MedImmune, LLC | Compositions and methods involving respiratory syncytial virus subgroup b strain 9320 |
| PT1699919T (pt) | 2003-12-24 | 2017-04-03 | De Staat Der Nederlanden Vertegenwoordigd Door De Mini Van Volksgezondheid Welzijn En Sport | Um vírus sincicial respiratório com deficiência genómica complementada em trans |
| CA2587084C (en) | 2004-10-08 | 2019-07-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonym ous codons |
| US7951384B2 (en) | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| WO2008133663A2 (en) | 2006-11-30 | 2008-11-06 | Government Of The United States Of America, As Represented By The Secretary, | Codon modified immunogenic compositions and methods of use |
| KR101621100B1 (ko) | 2007-03-30 | 2016-05-13 | 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 | 백신에 유용한 약독화 바이러스 |
| US8580270B2 (en) | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
| US9011876B2 (en) | 2008-11-05 | 2015-04-21 | Merck Sharp & Dohme Corp. | Live, attenuated respiratory syncytial virus |
| PL2370099T3 (pl) | 2008-12-09 | 2016-10-31 | Zmodyfikowane białka F RSV i sposoby ich zastosowania | |
| CA2768186A1 (en) | 2009-07-15 | 2011-01-20 | Novartis Ag | Rsv f protein compositions and methods for making same |
| US20110097358A1 (en) | 2009-10-12 | 2011-04-28 | Techno Vax, Inc. | RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) |
| US10227569B2 (en) | 2011-04-12 | 2019-03-12 | Emory University | Respiratory syncytial virus expression vectors |
| CA2835644C (en) * | 2011-05-13 | 2021-06-15 | Novartis Ag | Pre-fusion rsv f antigens |
| EP2729169A1 (en) | 2011-07-06 | 2014-05-14 | Nanobio Corporation | Human respiratory syncytial virus vaccine |
| US8816081B2 (en) | 2012-08-06 | 2014-08-26 | Basf Se | Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells |
| EP4190895A1 (en) | 2013-02-08 | 2023-06-07 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization |
| EP2970398B1 (en) * | 2013-03-13 | 2024-05-08 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
| US9738689B2 (en) * | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| EP3798310A1 (en) | 2013-03-14 | 2021-03-31 | Emory University | Recombinant rsv with silent mutations, vaccines, and methods related thereto |
| US9060975B2 (en) * | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
-
2016
- 2016-10-27 MX MX2018005462A patent/MX2018005462A/es unknown
- 2016-10-27 WO PCT/US2016/058976 patent/WO2017075125A1/en not_active Ceased
- 2016-10-27 CN CN201680072681.XA patent/CN108602858A/zh active Pending
- 2016-10-27 JP JP2018522569A patent/JP7311872B2/ja active Active
- 2016-10-27 KR KR1020187014777A patent/KR20180085730A/ko not_active Ceased
- 2016-10-27 BR BR112018008708-4A patent/BR112018008708A2/en not_active Application Discontinuation
- 2016-10-27 CA CA3003726A patent/CA3003726A1/en active Pending
- 2016-10-27 EP EP16860742.2A patent/EP3368547A4/en not_active Withdrawn
- 2016-10-27 US US15/772,275 patent/US11235050B2/en active Active
- 2016-10-27 SG SG11201803581VA patent/SG11201803581VA/en unknown
-
2022
- 2022-01-14 US US17/575,829 patent/US12257296B2/en active Active
-
2023
- 2023-04-13 JP JP2023065428A patent/JP2023100654A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180085730A (ko) | 2018-07-27 |
| CN108602858A (zh) | 2018-09-28 |
| EP3368547A1 (en) | 2018-09-05 |
| JP7311872B2 (ja) | 2023-07-20 |
| US20230293660A1 (en) | 2023-09-21 |
| US12257296B2 (en) | 2025-03-25 |
| MX2018005462A (es) | 2018-08-01 |
| EP3368547A4 (en) | 2019-06-05 |
| CA3003726A1 (en) | 2017-05-04 |
| US20180333477A1 (en) | 2018-11-22 |
| JP2019500320A (ja) | 2019-01-10 |
| US11235050B2 (en) | 2022-02-01 |
| WO2017075125A1 (en) | 2017-05-04 |
| BR112018008708A2 (en) | 2018-11-06 |
| JP2023100654A (ja) | 2023-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277069B (en) | Modified aminopurine compounds, their compositions and methods of treatment with them | |
| IL251527A0 (en) | Preparations of adenosine deaminase-2 (ada2), their variants and methods of using them | |
| ZA201701244B (en) | Carrier-antibody compositions and methods of making and using the same | |
| PL3557998T3 (pl) | Związki, kompozycje i sposoby ich stosowania | |
| SG11201803581VA (en) | Chimeric RSV, Immunogenic Compositions, and Methods of Use | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| GB201711635D0 (en) | Immunogenic composition | |
| GB201610599D0 (en) | Immunogenic Composition | |
| PL3373910T3 (pl) | Preparat echinomycyny, sposób wytwarzania i sposób stosowania | |
| SG11201705085UA (en) | Polymer composition, its method of preparation, its use and composition comprising it | |
| IL252683A0 (en) | Pyridyl-cycloalkyl-substituted carboxylic acids, preparations containing them and their medical uses | |
| EP3397277C0 (en) | IMMUNOGENIC COMPOSITION | |
| IL248256B (en) | Cyclohexenyl compounds, compositions comprising them and uses thereof | |
| GB201711637D0 (en) | Immunogenic composition | |
| GB201513614D0 (en) | Compositions, compounds and methods and uses relating thereto | |
| GB201614485D0 (en) | Immunogenic composition | |
| RO130539B8 (ro) | Compoziţie erbicidă, procedeu de preparare şi utilizarea acesteia | |
| GB201604755D0 (en) | Immunogenic compositions | |
| IL254597A0 (en) | Crystalline form of ahu377, method for its preparation and use | |
| GB201911959D0 (en) | Immunogenic compositions and uses therefor | |
| SG11201805812QA (en) | Delayed-release formulations, methods of making and use thereof | |
| EP3222611A4 (en) | Thickening and stabilizing agent, and thickening and stabilizing composition using same | |
| GB201501153D0 (en) | Immunogenic formulations | |
| GB201411371D0 (en) | Immunogenic composition | |
| GB201411306D0 (en) | Immunogenic composition |